19Dec
As its COVID-19 Vaccine Nears Finalization, AstraZeneca Announces Deal to Buy Alexion for $39 Billion
AstraZeneca, the British-Swedish multinational pharmaceutical company currently collaborating with the University of Oxford on a COVID-19 vaccine, will purchase Alexion Pharmaceuticals for $39 billion. The transaction, which awaits approval by shareholders and regulators, is the largest purchase by a health care company this year and is expected to close in the third quarter of 2021. Alexion was founded in 1992 and is headquartered in Boston but has a global presence. It is known for its...
By:
Rothwell, Figg, Ernst & Manbeck, P.C.
Related
IRAPs Arrive. On June 24, 2019, the U.S. Department of Labor’s (DOL) Employment and Training Admini...
Read More >
Foreign investment control has become a key factor in M&A deals and 2020 was a particularly eventfu...
Read More >
Recent insolvency law reforms in the UK, Singapore and Australia impact upon the ability of a party ...
Read More >
The DOJ’s Antitrust Division announced updates late last week to its Civil Investigative Demand (CI...
Read More >
Last week’s wild economic ride combined with China’s currency-devaluing response (and, arguably, m...
Read More >
The DE OFCCP Week in Review (WIR) is a simple, fast and direct summary of relevant happenings in the...
Read More >